Antifungal Activity of Brilacidin, a Nonpeptide Host Defense Molecule.

Larwood DJ, Stevens DA

Antibiotics (Basel, Switzerland)28 Apr 2024Cited by 6 (Europe PMC)

PMID38786134PMCIDPMC11117233DOI10.3390/antibiotics13050405PepBankPUB-38786134

Summary

Natural host defensins, also sometimes termed antimicrobial peptides, are evolutionarily conserved. They have been studied as antimicrobials, but some pharmaceutical properties, undesirable for clinical use, have led to the development of synthetic molecules with constructed peptide arrangements and/or peptides not found in nature. The leading development currently is synthetic small-molecule nonpeptide mimetics, whose physical properties capture the characteristics of the natural molecules and share their biological attributes. We studied brilacidin, an arylamide of this type, for its activity in vitro against fungi (40 clinical isolates, 20 species) that the World Health Organization has highlighted as problem human pathogens. We found antifungal activity at low concentrations for many pathogens, which indicates that further screening for activity, particularly in vivo, is justified to evaluate this compound, and other mimetics, as attractive leads for the development of effective antifungal agents.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In laboratory tests of fungal clinical isolates, brilacidin showed antifungal activity at low concentrations for many pathogens.
In plain wordsIn lab tests, brilacidin showed antifungal activity at low concentrations against many fungal pathogens.
Peptide
Brilacidin
Outcome
Not applicableAntifungal activity
Study
n: not reported in source
fungal clinical isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Source sentences
Summary
We found antifungal activity at low concentrations for many pathogens, which indicates that further screening for activity, particularly in vivo, is justified to evaluate this compound, and other mimetics, as attractive leads for the development of effective antifungal agents.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied brilacidin, an arylamide of this type, for its activity in vitro against fungi (40 clinical isolates, 20 species) that the World Health Organization has highlighted as problem human pathogens.
Show in the study text Report a problemFND-3878613401

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.